Program
Medroxyprogesterone Acetate
Also written as “Sayana Press”, “medroxyprogesterone acetate” and “TV-46046”.
Its studies are mostly in Neoplasms · Adenocarcinoma, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 50 open or running | phase 4since Jan 24, 2017 | May 10, 2007 | none ahead |
| Teva Pharmaceutical Industries | 40 open or running | phase 1since Jan 26, 2009 | Jan 26, 2009 | none ahead |
| Merck | 11 open or running | phase 2since May 13, 2025 | May 13, 2025 | Nov 4, 2027phase 2 · NCT06979596 |
| Takeda | 10 open or running | phase 3since Nov 3, 2009 | Nov 3, 2009 | none ahead |
Also a collaborator on its studies: mds-pharma-services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 10, 2007First study: phase 1 study in PostmenopauseNew to PfizerPfizer · NCT00472927 · United States
- Oct 3, 2007Phase 1 study in PostmenopausePfizer · NCT00543634 · 30 enrolled · United States
- Feb 28, 2008Phase 1 study in MenopausePfizer · NCT00630435 · 76 enrolled
- Jan 26, 2009Teva Pharmaceutical Industries's first study: phase 1 study in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00830414 · 124 enrolled · Germany
- Nov 3, 2009Takeda's first study: phase 3 study in AdenocarcinomaNew to TakedaTakeda · NCT01011751 · 311 enrolled · France
- Jun 27, 2016Phase 1 study in PregnancyTeva Pharmaceutical Industries · NCT02817464 · 12 enrolled · United States
- Jan 24, 2017Phase 4 study in ContraceptionPfizer · NCT03034057 · 169 enrolled · United Kingdom
- Oct 3, 2018Phase 1 study in ContraceptionTeva Pharmaceutical Industries · NCT03700658 · 27 enrolled · Dominican Republic
- Dec 4, 2020Phase 1 study in ContraceptionTeva Pharmaceutical Industries · NCT04682353 · 60 enrolled · United States, Dominican Republic
- May 14, 2021Phase 1 study in HealthyPfizer · NCT04893798 · 67 enrolled · Belgium
- May 13, 2025Merck's first study: phase 2 study in NeoplasmsNew to MerckMerck · NCT06979596 · 250 planned · United States, Argentina, Brazil and more
Ahead
- Nov 4, 2027Primary completion: phase 2 study in NeoplasmsMerck · NCT06979596
TargetBeta
“Progesterone receptor agonist”ChEMBL 37, by rule
Other programs on PGR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Levonorgestrelrule | Bayer | phase 4 | 56 |
| drospirenonerule | estetra | phase 4 | 20 |
| Megestrol Acetaterule | Changchun GeneScience Pharmaceutical | phase 4 | 19 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Utrogestanrule | calla-lily-clinical-care-ltd | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06979596Neoplasms · United States, Argentina, Brazil and more | 2 | Recruiting | Merck | Nov 4, 2027 | 250 |
| NCT04893798Healthy · Belgium | 1 | Completed | Pfizer | Jul 24, 2025 | 67 |
| NCT04682353Contraception · United States, Dominican Republic | 1 | Completed | Teva Pharmaceutical Industries | Jul 11, 2022 | 60 |
| NCT03700658Contraception · Dominican Republic | 1 | Completed | Teva Pharmaceutical Industries | Oct 2, 2020 | 27 |
| NCT03034057Contraception · United Kingdom | 4 | Completed | Pfizer | Dec 7, 2018 | 169 |
| NCT02817464Pregnancy · United States | 1 | Completed | Teva Pharmaceutical Industries | Dec 3, 2018 | 12 |
| NCT01011751Adenocarcinoma · France | 3 | Completed | Takeda | Dec 2007 | 311 |
| NCT00830414Healthy · Germany | 1 | Completed | Teva Pharmaceutical Industries | Sep 2002 | 124 |
| NCT00630435Menopause | 1 | Completed | Pfizer | Jun 2008 | 76 |
| NCT00543634Postmenopause · United States | 1 | Completed | Pfizer | Dec 2007 | 30 |
| NCT00472927Postmenopause · United States | 1 | Completed | Pfizer |
How it is read
Names in the registry
- “Sayana Press”, 2 entries
- “medroxyprogesterone acetate”, 2 entries
- “TV-46046”, 2 entries
- “Premarin/MPA”, 2 entries
- “Megestrol acetate/Medroxyprogesterone acetate”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 1 study
- Adenocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.